Patents by Inventor Wha Bin Im

Wha Bin Im has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Ester prodrugs of gamma-lactams and their use
    Patent number: 10329284
    Abstract: Described herein are ester prodrugs of gamma-lactam compounds of Formula (I): or pharmaceutically acceptable salt thereof, and methods of use of such compounds for the treatment of ocular diseases including, among other things, glaucoma and macular degeneration.
    Type: Grant
    Filed: October 2, 2015
    Date of Patent: June 25, 2019
    Assignee: ALLERGAN, INC.
    Inventors: Robert M. Burk, Wha Bin Im
  • Quaternary ammonium alkyl esters as stable prodrugs
    Patent number: 9981938
    Abstract: Disclosed herein are compounds according to Formulas 1-12, compositions comprising these compounds, and methods of lowering intraocular pressure (IOP) or causing hair growth, and methods of using the same.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: May 29, 2018
    Assignee: ALLERGAN, INC.
    Inventors: Robert M. Burk, David W. Old, Wha Bin Im, Richard S. Graham, Mu-Lan Lee
  • ESTER PRODRUGS OF GAMMA-LACTAMS AND THEIR USE
    Publication number: 20170298050
    Abstract: Described herein are ester prodrugs of gamma-lactam compounds of Formula (I): or pharmaceutically acceptable salt thereof, and methods of use of such compounds for the treatment of ocular diseases including, among other things, glaucoma and macular degeneration.
    Type: Application
    Filed: October 2, 2015
    Publication date: October 19, 2017
    Inventors: Robert M. Burk, Wha Bin Im
  • SKIN WOUND HEALING AND SCAR REDUCTION WITH PROSTAGLANDIN EP4 AGONIST COMBINATIONS
    Publication number: 20170151261
    Abstract: A combination of a prostaglandin EP4 agonist and an effective amount of: a prostaglandin EP2 agonist, a skin growth factor, a small peptide, a small inhibitory RNA targeting excess chronic inflammation or fibrosis, a cytokine with beneficial anti-inflammatory activity, an adenosine A2a receptor agonist, an anti-oxidant, or a combination thereof, may be used to treat skin wounds or scars.
    Type: Application
    Filed: July 1, 2016
    Publication date: June 1, 2017
    Inventors: Guang Liang Jiang, Robert M. Burk, Wha-Bin Im, Larry A. Wheeler
  • COMPOUNDS AND METHODS FOR SKIN REPAIR
    Publication number: 20170143733
    Abstract: The disclosure provides compositions and methods for wound healing and scar reduction. The compositions and methods of the invention include at least one mixed EP2/EP4 agonist set forth herein. Wounds and or scars that can be treated by the compositions and methods of the invention can arise from events such as surgery, trauma, disease, mechanical injury, burn, radiation, poisoning, and the like.
    Type: Application
    Filed: June 23, 2016
    Publication date: May 25, 2017
    Inventors: Robert M. Burk, Wha-Bin Im
  • Treatment of inflammatory bowel disease
    Patent number: 9637467
    Abstract: Disclosed herein is a method comprising administering a compound to a mammal suffering from an inflammatory bowel disease for the treatment of said disease, said compound having a structure according to Formula I wherein X, Y, B, R2, R3, R4, R5, R6 and n have the meanings found herein.
    Type: Grant
    Filed: September 4, 2015
    Date of Patent: May 2, 2017
    Assignee: ALLERGAN, INC.
    Inventors: Yariv Donde, Jeremiah H. Nguyen, Karen M. Kedzie, Daniel W. Gil, John E. Donello, Wha-Bin Im
  • QUATERNARY AMMONIUM ALKYL ESTERS AS STABLE PRODRUGS
    Publication number: 20170081304
    Abstract: Disclosed herein are compounds according to Formulas 1-12, compositions comprising these compounds, and methods of lowering intraocular pressure (IOP) or causing hair growth, and methods of using the same.
    Type: Application
    Filed: May 12, 2015
    Publication date: March 23, 2017
    Inventors: Robert M. Burk, David W. Old, Wha Bin Im, Richard S. Graham, Mu-Lan Lee
  • Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
    Patent number: 9427401
    Abstract: Compositions and methods for treating glaucoma are provided. In particular hydrophilic ester prodrugs and their use to reduce central corneal thickening is provided.
    Type: Grant
    Filed: April 13, 2015
    Date of Patent: August 30, 2016
    Assignee: ALLERGAN, INC.
    Inventors: Wha-Bin Im, Robert M. Burk
  • STABLE AQUEOUS COMPOSITIONS OF PROSTGLANDIN AGONIST PRODRUGS AND METHODS FOR USE THEREOF
    Publication number: 20160220677
    Abstract: The present invention is based on the discovery that a marked increase in aqueous stability (and thereby shelf life) of prostanoid agonist prodrug compositions is achieved by incorporating into the compositions certain well-defined carboxylic acids, and thereafter adjusting the pH of the compositions from about 4.0 to about 8.0. As a result, the compositions and methods of the invention provide the aqueous stability required for marketable topical drug treatments of a wide variety of ocular disorders.
    Type: Application
    Filed: August 26, 2015
    Publication date: August 4, 2016
    Inventors: Robert M. Burk, Wha-Bin Im
  • Bicyclic 1,3,4-oxadiazole derivatives as sphingosine-1-phosphate receptors' modulators
    Patent number: 9371296
    Abstract: The present invention relates to bicyclic 1,3,4-oxadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: June 21, 2016
    Assignee: Allergan, Inc.
    Inventors: Ling Li, Janet A. Takeuchi, Ken Chow, Wha Bin Im, Michael E. Garst
  • BICYCLIC 1,3,4-OXADIAZOLE DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTORS' MODULATORS
    Publication number: 20160137616
    Abstract: The present invention relates to bicyclic 1,3,4-oxadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
    Type: Application
    Filed: November 10, 2015
    Publication date: May 19, 2016
    Inventors: Ling Li, Janet A. Takeuchi, Ken Chow, Wha Bin Im, Michael E. Garst
  • Methods of treating soft tissue defects
    Patent number: 9334262
    Abstract: The specification discloses compositions and methods for treating a soft tissue defect of an individual.
    Type: Grant
    Filed: February 25, 2014
    Date of Patent: May 10, 2016
    Assignee: Allergan, Inc.
    Inventors: Dennis E. Van Epps, Guan-Liang Jiang, Wha Bin Im
  • TREATMENT OF INFLAMMATORY BOWEL DISEASE
    Publication number: 20160096817
    Abstract: Disclosed herein is a method comprising administering a compound to a mammal suffering from an inflammatory bowel disease for the treatment of said disease, said compound having a structure according to Formula I wherein X, Y, B, R2, R3, R4, R5, R6 and n have the meanings found herein.
    Type: Application
    Filed: September 4, 2015
    Publication date: April 7, 2016
    Inventors: Yariv Donde, Jeremiah H. Nguyen, Karen M. Kedzie, Daniel W. Gil, John E. Donello, Wha-Bin Im
  • REDUCED CENTRAL CORNEAL THICKENING BY USE OF HYDROPHILIC ESTER PRODRUGS OF BETA-CHLOROCYCLOPENTANES
    Publication number: 20150322036
    Abstract: Compositions and methods for treating glaucoma are provided. In particular hydrophilic ester prodrugs and their use to reduce central corneal thickening is provided.
    Type: Application
    Filed: April 13, 2015
    Publication date: November 12, 2015
    Inventors: Wha-Bin Im, Robert M. Burk
  • Treatment of inflammatory bowel disease
    Patent number: 9156810
    Abstract: Disclosed herein is a method comprising administering a compound to a mammal suffering from an inflammatory bowel disease for the treatment of said disease, said compound having a structure according to Formula I wherein X, Y, B, R2, R3, R4, R5, R6 and n have the meanings found herein.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: October 13, 2015
    Assignee: Allergan, Inc.
    Inventors: Yariv Donde, Jeremiah H. Nguyen, Karen M. Kedzie, Daniel W. Gil, John E. Donello, Wha-Bin Im
  • 1,3,4-oxadiazoles-2-thio azetidine derivatives as sphingosine-1 phosphate receptors modulators
    Patent number: 9120784
    Abstract: The present invention relates to substituted 1,3,4-oxadiazoles-2-thio azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
    Type: Grant
    Filed: November 4, 2013
    Date of Patent: September 1, 2015
    Assignee: Allergan, Inc.
    Inventors: Janet A. Takeuchi, Ling Li, Wha-Bin Im, Ken Chow
  • Pyrazole derivatives as sphingosine 1-phosphate (S1P) receptor modulators
    Patent number: 9108993
    Abstract: The present invention relates to pyrazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
    Type: Grant
    Filed: February 24, 2014
    Date of Patent: August 18, 2015
    Assignee: Allergan, Inc.
    Inventors: Janet A. Takeuchi, Ling Li, Wha Bin Im, Ken Chow
  • Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
    Patent number: 9090595
    Abstract: Compositions and methods for treating glaucoma are provided. In particular hydrophilic ester prodrugs and their use to reduce central corneal thickening is provided.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: July 28, 2015
    Assignee: Allergan, Inc.
    Inventors: Robert M. Burk, Wha Bin Im
  • Modulators of S1P receptors
    Patent number: 9079864
    Abstract: The present invention relates to novel diphenylethyne derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
    Type: Grant
    Filed: November 10, 2011
    Date of Patent: July 14, 2015
    Assignee: Allergan, Inc.
    Inventors: Santosh C. Sinha, Smita S. Bhat, Ken Chow, Michael E. Garst, Wha Bin Im
  • Pyrazole azetidine derivatives as sphingosine 1-phosphate (S1P) receptor modulators
    Patent number: 9062030
    Abstract: The present invention relates to pyrazole azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
    Type: Grant
    Filed: February 24, 2014
    Date of Patent: June 23, 2015
    Assignee: Allergan, Inc.
    Inventors: Janet A. Takeuchi, Ling Li, Wha Bin Im, Ken Chow